[1]
G. . Zauatbayeva, L. Syzdykova, V. . Keyer, A. Shustov, A. Abilmagzhanov, and M. Zhurynov, “NUCLEOSIDE ANALOG FAVIPIRAVIR IS A POOR INHIBITOR AGAINST THE SARS-COV-2 VIRUS IN CELL CULTURE, BUT FAVIPIRAVIR IS HIGHLY ACTIVE AGAINST VENEZUELAN EQUINE ENCEPHALITIS VIRUS”, Eurasian Journal of Applied Biotechnology, no. 2, pp. 44–53, Jul. 2022.